Sphingolipid metabolism in type 2 diabetes and associated cardiovascular complications

Sui,Jing; He,Mingqian; Wang,Yue; Zhao,Xinrui; He,Yizhi; Shi,Bingyin

doi:10.3892/etm.2019.7981

Sphingolipid metabolism in type 2 diabetes and associated cardiovascular complications

Authors:
- Jing Sui
- Mingqian He
- Yue Wang
- Xinrui Zhao
- Yizhi He
- Bingyin Shi
View Affiliations

Affiliations: Department of Endocrinology and International Medical Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Immunology and Rheumatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Endocrinology, Xi'an No. 3 Hospital, Xi'an, Shaanxi 710018, P.R. China
Published online on: September 6, 2019 https://doi.org/10.3892/etm.2019.7981
Pages: 3603-3614

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sphingolipid metabolism is dysregulated in type 2 diabetes mellitus (T2DM); however, the focus of previous studies was mostly limited to ceramide (Cer), and only few studies have investigated other metabolites, including sphingosine‑1 phosphate (So1P). The present study aimed to examine the involvement of 8 major sphingolipid metabolites, including Cer, glucosyl ceramide (GluCer), lactosyl ceramide (LacCer), sphingomyelin (SM), sphinganine (Sa), So1P, sphingosine (So) and sphinganine‑1‑phosphate (Sa1P), during the progression of T2DM, and to evaluate the ability of serum sphingolipids to predict cases of diabetes with an elevated risk of cardiovascular complications. Blood samples were obtained from 245 participants who were divided into 3 groups: Healthy controls, pre‑diabetes (pre‑DM) and diagnosed diabetes. The 8 major sphingolipid metabolites were measured by high‑performance liquid chromatography‑tandem mass spectrometry and blood parameters were determined by routine laboratory assays for all subjects. Among the sphingolipid metabolites, So1P was associated with sex and lean mass index, but not with the body mass index. So1P was highest in healthy controls and gradually decreased when the disease proceeded to pre‑DM and T2DM. GluCer, SM, Sa and So decreased in pre‑DM and rose again in T2DM, graphically exhibiting a ‘U’ shape change during the progression of diabetes. So1P and Sa were identified to be significantly associated with cardiovascular complications by multivariate logistic regression analysis. Receiver operating characteristic curve analysis also suggested that So1P and Sa were able to indicate cardiovascular complications in diabetic patients. Pre‑DM and diabetes were significantly associated with decreased So1P, SM, Sa and So, compared with the healthy controls. So1P was correlated with the progression of T2DM, and was a predictor of an elevated risk of cardiovascular complications among T2DM patients, along with Sa. The present study was registered with ClinicalTrials.gov (no. NCT02826759; April 2016).

View Figures

View References

1	Mathers CD and Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3:e4422006. View Article : Google Scholar : PubMed/NCBI
2	Wong ND: Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 11:276–289. 2014. View Article : Google Scholar : PubMed/NCBI
3	American Diabetes Association: 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabete-2019. Diabetes Care. 42 (Suppl 1):S103–S123. 2019. View Article : Google Scholar : PubMed/NCBI
4	Tonks KT, Coster AC, Christopher MJ, Chaudhuri R, Xu A, Gagnon-Bartsch J, Chisholm DJ, James DE, Meikle PJ, Greenfield JR and Samocha-Bonet D: Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humans. Obesity (Silver Spring). 24:908–916. 2016. View Article : Google Scholar : PubMed/NCBI
5	Chaurasia B, Kaddai VA, Lancaster GI, Henstridge DC, Sriram S, Galam DL, Gopalan V, Prakash KN, Velan SS, Bulchand S, et al: Adipocyte ceramides regulate subcutaneous adipose browning, inflammation, and metabolism. Cell Metab. 24:820–834. 2016. View Article : Google Scholar : PubMed/NCBI
6	Meikle PJ and Summers SA: Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nat Rev Endocrinol. 13:79–91. 2017. View Article : Google Scholar : PubMed/NCBI
7	Samad F, Badeanlou L, Shah C and Yang G: Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity. Adv Exp Med Biol. 721:67–86. 2011. View Article : Google Scholar : PubMed/NCBI
8	Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, Knotts TA, Shui G, Clegg DJ, Wenk MR, et al: Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest. 121:1858–1870. 2011. View Article : Google Scholar : PubMed/NCBI
9	Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, et al: Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 17:55–63. 2011. View Article : Google Scholar : PubMed/NCBI
10	Rauch BH: Sphingosine 1-phosphate as a link between blood coagulation and inflammation. Cell Physiol Biochem. 34:185–96. 2014. View Article : Google Scholar : PubMed/NCBI
11	Soltau I, Mudersbach E, Geissen M, Schwedhelm E, Winkler MS, Geffken M, Peine S, Schoen G, Debus ES, Larena-Avellaneda A and Daum G: Serum-sphingosine-1-phosphate concentrations are inversely associated with atherosclerotic diseases in humans. PLoS One. 11:e01683022016. View Article : Google Scholar : PubMed/NCBI
12	Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults, . Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi. 35:390–419. 2007.(In Chinese). PubMed/NCBI
13	Zhou BF; Cooperative Meta-Analysis Group of the Working Group on Obesity in China, : Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults-study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 15:83–96. 2002.PubMed/NCBI
14	Gómez-Ambrosi J, Silva C, Catalán V, Rodríguez A, Galofré JC, Escalada J, Valentí V, Rotellar F, Romero S, Ramírez B, et al: Clinical usefulness of a new equation for estimating body fat. Diabetes Care. 35:383–388. 2012. View Article : Google Scholar : PubMed/NCBI
15	Grammatikos G, Schoell N, Ferreirós N, Bon D, Herrmann E, Farnik H, Köberle V, Piiper A, Zeuzem S, Kronenberger B, et al: Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma. Oncotarget. 7:18095–18105. 2016. View Article : Google Scholar : PubMed/NCBI
16	Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA and Kirwan JP: Plasma ceramides are elevated in obese subjects with Type 2 diabetes and correlate with the severity of insulin resistance. Diabetes. 58:337–343. 2009. View Article : Google Scholar : PubMed/NCBI
17	Yaghobian D, Don AS, Yaghobian S, Chen X, Pollock CA and Saad S: Increased sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy. Clin Exp Pharmacol Physiol. 43:56–66. 2016. View Article : Google Scholar : PubMed/NCBI
18	Egom EE, Mamas MA, Chacko S, Stringer SE, Charlton-Menys V, El-Omar M, Chirico D, Clarke B, Neyses L, Cruickshank JK, et al: Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury. Front Physiol. 4:1302013. View Article : Google Scholar : PubMed/NCBI
19	Sasset L, Zhang Y, Dunn TM and Di Lorenzo A: Sphingolipid de novo biosynthesis: A rheostat of cardiovascular homeostasis. Trends Endocrinol Metab. 27:807–819. 2016. View Article : Google Scholar : PubMed/NCBI
20	Mi S, Zhao YY, Dielschneider RF, Gibson SB and Curtis JM: An LC/MS/MS method for the simultaneous determination of individual sphingolipid species in B cells. J Chromatogr B Analyt Technol Biomed Life Sci. 1031:50–60. 2016. View Article : Google Scholar : PubMed/NCBI
21	Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM, Mauer J, Xu E, Hammerschmidt P, Brönneke HS, et al: Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 20:678–686. 2014. View Article : Google Scholar : PubMed/NCBI
22	Boini KM, Zhang C, Xia M, Poklis JL and Li PL: Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther. 334:839–846. 2010. View Article : Google Scholar : PubMed/NCBI
23	Awad AS, Rouse MD, Khutsishvili K, Huang L, Bolton WK, Lynch KR and Okusa MD: Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int. 79:1090–1098. 2011. View Article : Google Scholar : PubMed/NCBI
24	Mielke MM, Haughey NJ, Han D, An Y, Bandaru VVR, Lyketsos CG, Ferrucci L and Resnick SM: The association between plasma ceramides and sphingomyelins and risk of Alzheimer's disease differs by sex and APOE in the baltimore longitudinal study of aging. J Alzheimers Dis. 60:819–828. 2017. View Article : Google Scholar : PubMed/NCBI
25	Gale EA and Gillespie KM: Diabetes and sex. Diabetologia. 44:3–15. 2001. View Article : Google Scholar : PubMed/NCBI
26	Peters SA, Huxley RR and Woodward M: Diabetes as a risk factor for stroke in women compared with men: A systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 383:1973–1980. 2014. View Article : Google Scholar : PubMed/NCBI
27	Miyamoto S, Hsu CC, Hamm G, Darshi M, Diamond-Stanic M, Declèves AE, Slater L, Pennathur S, Stauber J, Dorrestein PC and Sharma K: Mass spectrometry imaging reveals elevated glomerular ATP/AMP in diabetes/obesity and identifies sphingomyelin as a possible mediator. EBioMedicine. 7:121–134. 2016. View Article : Google Scholar : PubMed/NCBI
28	Chavez JA, Siddique MM, Wang ST, Ching J, Shayman JA and Summers SA: Ceramides and glucosylceramides are independent antagonists of insulin signaling. J Biol Chem. 289:723–734. 2014. View Article : Google Scholar : PubMed/NCBI
29	Górska M, Dobrzyń A and Baranowski M: Concentrations of sphingosine and sphinganine in plasma of patients with Type 2 diabetes. Med Sci Monit. 11:CR35–CR38. 2005.PubMed/NCBI
30	Rütti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S, Meier DT, Niclauss N, Berney T, Donath MY and von Eckardstein A: Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology. 150:4521–4530. 2009. View Article : Google Scholar : PubMed/NCBI
31	Taguchi Y, Allende ML, Mizukami H, Cook EK, Gavrilova O, Tuymetova G, Clarke BA, Chen W, Olivera A and Proia RL: Sphingosine-1-phosphate phosphatase 2 regulates pancreatic islet beta-cell endoplasmic reticulum stress and proliferation. J Biol Chem. 291:12029–12038. 2016. View Article : Google Scholar : PubMed/NCBI
32	Alshehry ZH, Mundra PA, Barlow CK, Mellett NA, Wong G, McConville MJ, Simes J, Tonkin AM, Sullivan DR, Barnes EH, et al: Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus. Circulation. 134:1637–1650. 2016. View Article : Google Scholar : PubMed/NCBI
33	Liu G, Yang K, Burns S, Shrestha S and Chi H: The S1P (1)-mTOR axis directs the reciprocal differentiation of T (H)1 and T (reg) cells. Nat Immunol. 11:1047–1056. 2010. View Article : Google Scholar : PubMed/NCBI
34	Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, et al: CD8⁺ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 15:914–920. 2009. View Article : Google Scholar : PubMed/NCBI
35	Murakami A, Takasugi H, Ohnuma S, Koide Y, Sakurai A, Takeda S, Hasegawa T, Sasamori J, Konno T, Hayashi K, et al: Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: Investigation based on a new S1P3 receptor antagonist. Mol Pharmacol. 77:704–713. 2010. View Article : Google Scholar : PubMed/NCBI
36	Nofer JR, van der Giet M, Tölle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Gödecke A, Ishii I, Kleuser B, et al: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 113:569–581. 2004. View Article : Google Scholar : PubMed/NCBI